Analysts hike Cangene price targets
October 23, 2009 by leonardzehr · Leave a Comment
Versant Partners raised its 12-month price target on Cangene (TSX:CNJ) to $11 from $10 after the drug maker’s fiscal 2009 profit blew through analysts’ forecasts. On Thursday, Winnipeg-based Cangene reported a profit gain of 102% on revenue 44% higher for the fiscal year ended July 31, sending its stock price soaring $1.84 to $6.39. Versant [...]
Listen to BioTuesdays 
